| Q33826278 | 3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1 |
| Q37980177 | A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea]). |
| Q30369008 | A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections |
| Q24563844 | A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides |
| Q37255082 | Clinical use of vaginal or rectally applied microbicides in patients suffering from HIV/AIDS. |
| Q35842270 | Clinical utility of current NNRTIs and perspectives of new agents in this class under development |
| Q33770052 | Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection |
| Q36803970 | Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay |
| Q40465731 | Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B). |
| Q36482710 | Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]dapivirine for 7 days. |
| Q37984498 | Current and future microbicide approaches aimed at preventing HIV infection in women. |
| Q37253552 | Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues |
| Q37990037 | Drug delivery in multiple indication (multipurpose) prevention technologies: systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 transmission |
| Q37705969 | Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection |
| Q36458398 | Emerging reverse transcriptase inhibitors for the treatment of HIV infection in adults |
| Q37853935 | HIV sexual transmission and microbicides |
| Q58994217 | High-Performance Liquid Chromatographic Method for Analysis of Emtricitabine in Rat Plasma: Method Development, Validation and Application to a Pharmacokinetic Study |
| Q36744775 | Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection |
| Q34737547 | Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides |
| Q34647446 | In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1 |
| Q39518073 | In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection |
| Q35689311 | In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine |
| Q33598736 | Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir |
| Q37072072 | Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor |
| Q39265131 | Intravaginal rings: controlled release systems for contraception and prevention of transmission of sexually transmitted infections |
| Q37713059 | MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection |
| Q36750849 | Microbicide drug candidates to prevent HIV infection |
| Q30359545 | Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections. |
| Q37766845 | Microbicides in the prevention of HIV infection: current status and future directions |
| Q27022779 | Microbicides: a new hope for HIV prevention |
| Q55338133 | Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis. |
| Q37657512 | Nanoparticle-based vaginal drug delivery systems for HIV prevention |
| Q24569706 | Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore |
| Q36632128 | Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase |
| Q55170368 | Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies. |
| Q38812689 | Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring. |
| Q33826304 | Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection |
| Q37657468 | Pharmaceutical development of microbicide drug products |
| Q36143276 | Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention |
| Q45010869 | Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices |
| Q57570872 | Polymeric Nanoparticles Affect the Intracellular Delivery, Antiretroviral Activity and Cytotoxicity of the Microbicide Drug Candidate Dapivirine |
| Q28469069 | Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol |
| Q90315006 | Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline |
| Q45010861 | Preclinical evaluation of UC781 microbicide vaginal drug delivery |
| Q84509129 | Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV |
| Q24559813 | Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicide |
| Q37428359 | RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models |
| Q37190754 | Reverse transcriptase inhibitors as potential colorectal microbicides |
| Q33303221 | Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring |
| Q33923694 | The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma |
| Q30414890 | The importance of the vaginal delivery route for antiretrovirals in HIV prevention |
| Q33930525 | The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells |
| Q36749580 | The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics |
| Q36086344 | UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application |
| Q37149107 | Vaginal drug delivery systems for HIV prevention |
| Q37063819 | Vaginal microbicides and the prevention of HIV transmission |
| Q36429890 | Vaginal rings for delivery of HIV microbicides. |
| Q35766254 | siRNA-based topical microbicides targeting sexually transmitted infections. |